Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
3.
Australas J Dermatol ; 64(2): 272-277, 2023 May.
Article in English | MEDLINE | ID: mdl-36745433

ABSTRACT

We herein present a unique patient of Netherton syndrome (NS) with ichthyosis linearis circumflexa (ILC) lesions associated with severe atopic manifestations since infancy, showing different responses of atopic and ILC lesions to a 2-year dupilumab therapy. The atopic eczematous lesions and pruritus healed remarkably, dramatically improving the patient's quality of life, whilst the scalp hair showed a clinical and light microscopic improvement. The additional recovery in axillary/pubic/extremity hair growth, sweating and nail growth in the presented case was not previously reported in NS patients treated with dupilumab. However, dupilumab had no therapeutic effect on ILC lesions which were not pruritic and showed a treatment-independent wax and waned course.


Subject(s)
Dermatitis, Atopic , Netherton Syndrome , Humans , Netherton Syndrome/complications , Netherton Syndrome/drug therapy , Netherton Syndrome/pathology , Quality of Life , Dermatitis, Atopic/complications , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/pathology , Antibodies, Monoclonal, Humanized/therapeutic use
4.
Pediatr Allergy Immunol ; 34(1): e13914, 2023 01.
Article in English | MEDLINE | ID: mdl-36705039

ABSTRACT

BACKGROUND: Netherton syndrome (NS; OMIM: 256500) is a rare autosomal recessively inherited disease due to SPINK5 mutations. Hair and inflammatory skin involvement are variable along with allergies. Morbidity and mortality are high, particularly in infancy. A detailed clinical analysis of a NS patient cohort should broaden the understanding of nutritional challenges and allergic comorbidities. METHODS: In this retrospective monocentric cohort study, medical and dietetic records of pediatric NS patients, presenting between 1999 and 2018, were reviewed. The severity of skin involvement was assessed according to the extent of the body surface area (BSA) affected by erythema. RESULTS: We identified 21 patients with NS (median age 11.6 years). Within the first 6 months of life, requirements for fluid and kcals/protein were high for all patients (average 228 ml/kg/day) and infants had an average of 1.9 feed changes (range 0-4) due to food intolerance. Clinical evidence for IgE-mediated food allergy was present in 84.2% (16/19 children, 2 no data) with a range of 1-12 food allergies per patient. In 75%, more than one food had to be avoided. Specific IgE levels were falsely positive in 38.3% and 8/18 patients (44.4%). One-third (5/15; 6 no data) of patients, all with severe disease, had anaphylactic reactions following ingestion of fish (n = 2), sesame (n = 1), cow's milk (n = 1), and both peanut and egg (n = 1). CONCLUSIONS: Our data emphasize feeding difficulties in children with NS and reveal an unexpectedly higher prevalence of food allergies that gives evidence to the importance of early coordinated multidisciplinary care for overcoming these challenges in NS.


Subject(s)
Food Hypersensitivity , Malnutrition , Milk Hypersensitivity , Netherton Syndrome , Animals , Humans , Allergens , Cohort Studies , Immunoglobulin E , Malnutrition/complications , Netherton Syndrome/epidemiology , Netherton Syndrome/complications , Prevalence , Retrospective Studies , Risk Factors , Child
5.
JAMA Dermatol ; 158(11): 1315, 2022 11 01.
Article in English | MEDLINE | ID: mdl-36169939

ABSTRACT

This case report describes dry skin with marked redness of the face and hands as well as trichorrhexis invaginata.


Subject(s)
Dermatitis, Exfoliative , Netherton Syndrome , Humans , Netherton Syndrome/complications , Netherton Syndrome/diagnosis , Netherton Syndrome/genetics , Dermoscopy
6.
Australas J Dermatol ; 63(3): 365-367, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35622930

ABSTRACT

Netherton syndrome is a rare, severe genetic disorder of cornification without specific treatment. We describe two cases who demonstrated marked cutaneous improvement with secukinumab and suggest a role for IL-17 therapy in treating this condition.


Subject(s)
Ichthyosis , Netherton Syndrome , Skin Neoplasms , Antibodies, Monoclonal, Humanized , Hair , Humans , Netherton Syndrome/complications , Netherton Syndrome/drug therapy
7.
J Eur Acad Dermatol Venereol ; 36(7): 973-986, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35238435

ABSTRACT

The broad differential diagnosis of neonatal erythroderma often poses a diagnostic challenge. Mortality of neonatal erythroderma is high due to complications of the erythroderma itself and the occasionally severe and life-threatening underlying disease. Early correct recognition of the underlying cause leads to better treatment and prognosis. Currently, neonatal erythroderma is approached on a case-by-case basis. The purpose of this scoping review was to develop a diagnostic approach in neonatal erythroderma. After a systematic literature search in Embase (January 1990 - May 2020, 74 cases of neonatal erythroderma were identified, and 50+ diagnoses could be extracted. Main causes were the ichthyoses (40%) and primary immunodeficiencies (35%). Congenital erythroderma was present in 64% (47/74) of the cases, predominantly with congenital ichthyosis (11/11; 100%), Netherton syndrome (12/14, 86%) and Omenn syndrome (11/23, 48%). Time until diagnosis ranged from 102 days to 116 days for cases of non-congenital erythroderma and congenital erythroderma respectively. Among the 74 identified cases a total of 17 patients (23%) died within a mean of 158 days and were related to Omenn syndrome (35%), graft-versus-host disease (67%) and Netherton syndrome (18%). Disease history and physical examination are summarized in this paper. Age of onset and a collodion membrane can help to narrow the differential diagnoses. Investigations of blood, histology, hair analysis, genetic analysis and clinical imaging are summarized and discussed. A standard blood investigation is proposed, and the need for skin biopsies with lympho-epithelial Kazal-type related Inhibitor staining is highlighted. Overall, this review shows that diagnostic procedures narrow the differential diagnosis in neonatal erythroderma. A 6-step flowchart for the diagnostic approach for neonatal erythroderma during the first month of life is proposed. The approach was made with the support of expert leaders from international multidisciplinary collaborations in the European Reference Network Skin-subthematic group Ichthyosis.


Subject(s)
Dermatitis, Exfoliative , Ichthyosis, Lamellar , Ichthyosis , Netherton Syndrome , Severe Combined Immunodeficiency , Dermatitis, Exfoliative/etiology , Diagnosis, Differential , Humans , Ichthyosis/genetics , Infant, Newborn , Netherton Syndrome/complications , Severe Combined Immunodeficiency/complications
8.
S D Med ; 75(12): 554-556, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36893349

ABSTRACT

Netherton syndrome (NS) is a rare autosomal recessive condition caused by mutations in the serine peptidase inhibitor, Kazal type 5 (SPINK5) gene which encodes for a serine protease inhibitor, lymphoepithelial Kazal-typerelated inhibitor (LEKT1). NS is characterized by a triad of ichthyosiform erythroderma, trichorrhexis invaginata, and atopic diathesis with elevated IgE levels. The syndrome typically presents in infancy, where life-threatening complications are frequent, and evolves into a less severe condition with milder clinical symptoms in adulthood. This case report details the clinical history and genetic testing of a mother and two children with clinically symptomatic and genetically proven NS.


Subject(s)
Ichthyosiform Erythroderma, Congenital , Netherton Syndrome , Humans , Child , Female , Netherton Syndrome/complications , Netherton Syndrome/diagnosis , Netherton Syndrome/genetics , Mothers , Serine Peptidase Inhibitor Kazal-Type 5/genetics , Ichthyosiform Erythroderma, Congenital/genetics , Mutation , Serine Proteinase Inhibitors/genetics
11.
J Invest Dermatol ; 141(1): 114-123, 2021 01.
Article in English | MEDLINE | ID: mdl-32553662

ABSTRACT

Atopic dermatitis (AD) is an inflammatory skin disease in which epidermal barrier impairment, often owing to FLG null mutations, precedes immune hyperresponsiveness. Ichthyosis vulgaris is characterized by FLG null mutations and noninflamed dry skin. Netherton syndrome (NS), caused by SPINK5 null mutations, is characterized by generalized erythroderma with scaling and atopic manifestations. The goal of this work was to evaluate associations between specific skin disease features, such as ichthyotic and/or atopic manifestations, and the skin bacterial and fungal microbiota. Taxon diversity showed greater variation in the bacterial microbiota than in the fungal microbiota in the skin diseases. The relative abundances of Firmicutes (Staphylococcus) and Actinobacteria (Corynebacterium) were augmented in ichthyosis vulgaris, AD, and NS, whereas those of Proteobacteria/Enhydrobacter and Bacteroidetes were reduced, regardless of body site. Furthermore, proportions of Staphylococcus were correlated with transepidermal water loss and serum IgE levels. Nevertheless, the skin of patients with low to mild AD was overcolonized with Staphylococcus epidermidis and not with Staphylococcus aureus. Ascomycota were increased in both AD and NS, but from expansion of different fungal species. Finally, the expansion of pathologic bacteria in AD and NS might be supported by surrounding fungi. Thus, distinguishable bacterial and fungal skin dysbiosis in AD, NS, and ichthyosis vulgaris emphasizes disease-specific pathomechanisms.


Subject(s)
Bacteria/isolation & purification , Dermatitis, Atopic/microbiology , Dysbiosis/microbiology , Fungi/isolation & purification , Microbiota , Netherton Syndrome/microbiology , Skin/microbiology , Adult , Dermatitis, Atopic/complications , Dermatitis, Atopic/pathology , Dysbiosis/complications , Female , Filaggrin Proteins , Humans , Male , Netherton Syndrome/complications , Netherton Syndrome/pathology , Skin/pathology
13.
JAMA Dermatol ; 156(8): 907-911, 2020 08 01.
Article in English | MEDLINE | ID: mdl-32459284

ABSTRACT

Importance: Netherton syndrome (NS) is a rare, severe genetic disorder of cornification with high morbidity. Treatment for NS has been notoriously difficult. Recent studies showed an upregulated helper T cell (TH) 17/interleukin 23 (IL-23) pathway in NS, suggesting the possibility of treatment strategies that target IL-17. Objective: To evaluate the clinical response of NS to treatment with the IL-17 antagonist secukinumab. Design, Setting, and Participants: This case series study reports the experience of compassionate use therapy with secukinumab in 4 patients with severe NS, including 2 children, from December 1, 2018, to December 1, 2019, with 3 patients still undergoing treatment at the time of final analysis. Data were analyzed from December 1, 2018, to December 1, 2019. Main Outcomes and Measures: Expression of IL-17 in the skin was evaluated by immunohistochemical analysis, and serum cytokine concentrations were measured using a commercially available assay. Treatment response was assessed using the Ichthyosis Area and Severity Index (IASI) total score, including measures of erythema and scaling, the Dermatology Life Quality Index (DLQI), and the 5-D itch scale. Results: In all 4 patients (age range, 9-27 years; 3 male and 1 female), immunostaining with an IL-17A antibody showed an increased number of positive cells in lesional skin. Cytokine assessment in serum samples revealed increased levels of CCL20. Treatment duration with secukinumab was 3 to 12 months at the time of this report. After 3 months of therapy, IASI scores were reduced by 44% to 88%, DLQI scores were reduced by 40% to 76%, and 5-D itch scale scores were reduced by 27% to 62%. This outcome was sustained at the 6-month follow-up. Two patients with an erythrodermic phenotype showed marked improvement of all parameters. A refractory palmoplantar eczematous eruption occurred in 2 patients, and a candidal nail infection developed in 2 patients. No severe adverse events were reported. Conclusions and Relevance: This initial case series reporting the use of anti-IL-17 therapy in NS demonstrated marked cutaneous improvement, particularly in 2 pediatric patients with erythrodermic phenotypes. Further studies are needed to evaluate the long-term benefit of this potential treatment modality.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Dermatologic Agents/therapeutic use , Netherton Syndrome/drug therapy , Adult , Antibodies, Monoclonal, Humanized/adverse effects , Chemokine CCL20/blood , Child , Compassionate Use Trials , Dermatologic Agents/adverse effects , Female , Humans , Interleukin-17/metabolism , Male , Netherton Syndrome/complications , Netherton Syndrome/metabolism , Onychomycosis/chemically induced , Phenotype , Pruritus/etiology , Quality of Life , Severity of Illness Index , Skin/metabolism , Young Adult
17.
BMJ Case Rep ; 11(1)2018 Nov 28.
Article in English | MEDLINE | ID: mdl-30567081

ABSTRACT

A 21-year-old man with Netherton syndrome underwent investigation of a persistently elevated serum alanine transaminase, detected on routine monitoring. He drank no alcohol, was not diabetic or overweight (body mass index 23 kg/m2) and had no clinical features of liver dysfunction. A FibroScan yielded an elevated result of 9.3 kPa. An ultrasound guided liver biopsy showed histological features consistent with non-alcoholic steatohepatitis, with activity score of 4 and fibrosis stage of 3. The patient was started on vitamin E supplementation and remains under surveillance.


Subject(s)
Netherton Syndrome/complications , Non-alcoholic Fatty Liver Disease/etiology , Alanine Transaminase/blood , Dietary Supplements , Humans , Male , Netherton Syndrome/blood , Non-alcoholic Fatty Liver Disease/therapy , Vitamin E/therapeutic use , Vitamins/therapeutic use , Young Adult
18.
J Dermatol Sci ; 92(2): 127-133, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30241690

ABSTRACT

BACKGROUND: Congenital ichthyoses (CIs) adversely affect quality of life (QOL) in patients. However, the effects of CIs on patient QOL have not been studied sufficiently. OBJECTIVE: To investigate the association between disease severity and QOL in patients with harlequin ichthyosis (HI) and ichthyosis: syndromic forms (ISFs) METHODS: Clinical information of patients with HI and ISFs from 2010 to 2015 were obtained from 100 dermatology departments/divisions of principal institutes/hospitals throughout Japan. We examined the relationship between disease severity and QOL in patients with HI and ISFs. Patients who were aged 8 years or older and participated in a multicenter retrospective questionnaire survey in Japan were assessed by dermatology life quality index (DLQI, range of 0-30) and clinical ichthyosis score (range of 0-100). RESULTS: Netherton syndrome patients had a significantly higher risk of allergy to food or environmental allergens than patients with other phenotypes. Keratitis-ichthyosis-deafness (KID) syndrome patients showed a significantly higher risk of skin infections than patients with other phenotypes. Complete data on DLQI were obtained from 13 patients, whose median age was 21 (8-71) years. Nine patients were male, and 4 were female. Systemic retinoids were administrated to 2 of the 3 HI patients. The Spearman's correlation coefficient between the clinical ichthyosis score and DLQI was 0.611 (P < 0.05). CONCLUSION: We confirmed that Netherton syndrome and KID syndrome patients have a higher risk of allergy to food or environmental allergens and of skin infections, respectively. QOL impairment correlates with disease severity in HI and ISFs patients.


Subject(s)
Hypersensitivity, Immediate/epidemiology , Ichthyosis, Lamellar/complications , Keratitis/complications , Netherton Syndrome/complications , Quality of Life , Skin Diseases, Infectious/epidemiology , Adolescent , Adult , Aged , Allergens/immunology , Child , Cross-Sectional Studies , Environmental Exposure/adverse effects , Female , Humans , Ichthyosis, Lamellar/diagnosis , Japan/epidemiology , Keratitis/diagnosis , Male , Middle Aged , Netherton Syndrome/diagnosis , Retrospective Studies , Severity of Illness Index , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...